Get To Know Us

Dave Richards

David Richards

Chief Executive Officer

Board Member

David Richards is a life sciences executive with expertise in corporate development, team building, operations, capital structuring, research and development, program management, and intellectual property development. Mr. Richards has served as Chief Executive Officer of Clarametyx Biosciences since 2020. Prior to Clarametyx, Mr. Richards served in executive roles for Aclipse Therapeutics, which focuses on molecular pathways that regulate cellular stress, protein misfolding and inflammation in neurodegenerative and gastrointestinal disease areas; and N8 Biosciences, Inc., which is commercializing novel small molecule antimicrobial therapeutics and device coatings that mimic naturally occurring antimicrobial peptides. Prior to these roles, Mr. Richards served in operational and legal capacities for various startups, family office funds and was an associate at a large multinational law firm Latham & Watkins LLP. Mr. Richards received a bachelor’s degree in economics from Vanderbilt University and his JD from the University of Texas School of Law.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.